QDELQuidelOrtho Corporation
The Read
QuidelOrtho's stock initially held near its bear floor despite Q4 beats due to margin and respiratory segment concerns, then plunged over 22% on liquidity fears and debt worries after institutional selling and CFO departure, and finally collapsed nearly 38% more amid negative sentiment and massive JPMorgan sell-off following a disappointing strategic update.
The schedule
- Thu15Oct
Management provides a scheduled update on the commercial rollout of the Savanna multiplex molecular testing platform and core immunodiagnostics traction.
- Mon11Jan
QuidelOrtho presents at the annual J.P. Morgan Healthcare Conference, offering a critical venue to preview FY2027 guidance and update its strategic cost-synergy initiatives.
- Wed3Feb
Q3 2026 results face intense scrutiny over capital allocation as the market evaluates QuidelOrtho's ability to service its debt structure amid sluggish organic diagnostic volume.
- Tue9Feb
The year-end Q4 2026 earnings report serves as the formal introduction for FY2027 financial guidance, a pivotal moment for tracking debt covenant compliance.
- Tue11May
Q1 2027 results evaluate the early impact of President Trump's trade and regulatory policies on medical device supply chains, alongside base business volumes.
Past
- Wed5Aug
Actual outcome: Bear
Despite beating Q2 top- and bottom-line estimates with 3% reported revenue growth, QuidelOrtho lowered its full-year outlook and withdrew its free cash flow guidance due to continued pressure in China and a softer respiratory testing environment. Given the market's intense focus on the company's ability to service its $2.87 billion debt load, the withdrawal of cash flow guidance sparked a severe sell-off that drove shares well below the bear floor.
QuidelOrtho reports Q2 2026 results following a sharp technical bounce to $18.00, placing immense focus on free cash flow generation and the company's $2.87B debt load.
- Wed1Apr
Actual outcome: Bear · $10.32 at outcome
QuidelOrtho shares plummeted 37.8% following the event date, breaking well below the $15.50 bear floor to close at $10.32. The steep decline was driven by overwhelmingly negative market sentiment, highlighted by an average 'Reduce' rating from brokerages and a massive 85.6% reduction in holdings by major institutional investor JPMorgan Chase. Without a positive catalyst from the strategic update to reverse the momentum, selling pressure pushed the stock to new 52-week lows.
- Tue10Mar
Actual outcome: Bear · $16.58 at outcome
QuidelOrtho's stock price collapsed well below the $19.50 bear floor to $17.10 as the market focused on a 24.5% decline since its last earnings report, driven by sustained negative free cash flow and a $2.8B debt burden. Institutional selling by ArrowMark Colorado Holdings and the retirement of the CFO further signaled a lack of confidence in the company's near-term liquidity and synergy execution, validating the bear case.
- Tue10Feb
Actual outcome: Bear · $23.13 at outcome
QuidelOrtho delivered a Q4 EPS and revenue beat, and provided positive FY2026 guidance expecting continued growth, margin expansion, and over $200 million in free cash flow improvement. Despite these fundamentally bullish results, the stock failed to clear the bull target and remained near the bear floor, likely due to market focus on shrinking margins and weakness in the respiratory segment offsetting the headline beats.
